HIV-1 trans-activating (Tat) protein Both a target and a tool in therapeutic approaches

Biochemical Pharmacology

Volumn 58, Issue 10, 1999, Pages 1521-1528

  Watson, Keith ^a   Edwards, Robert J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Basic domain; tat; Trans activation; Translocation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TRANSACTIVATOR PROTEIN;

DRUG DEVELOPMENT; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; TRANSACTIVATION;

EID: 0032868710     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00209-9     Document Type: Article

References (89)

1. Greene W.C. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 324:1991;308-317.
2. Vaishnav Y.N., Wong-Staal F. The biochemistry of AIDS. Annu Rev Biochem. 60:1991;577-630.
3. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 57:1993;183-289.
4. Kingsman S.M., Kingsman A.J. The regulation of human immunodeficiency virus type-1 gene expression. Eur J Biochem. 240:1996;491-507.
5. Schwartz S., Felber B.K., Fenyö E.-M., Pavlakis G.N. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol. 64:1990;5448-5456.
6. Kim S.Y., Byrn R., Groopman J., Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection Evidence for differential gene expression . J Virol. 63:1989;3708-3713.
7. Barillari G., Gendelman R., Gallo R.C., Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA. 90:1993;7941-7945.
8. Garcia J.A., Harrich D., Pearson L., Mitsuyasu R., Gaynor R.B. Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J. 7:1988;3143-3147.
9. Ruben S., Perkins A., Purcell R., Joung K., Sia R., Burghoff R., Haseltine W.A., Rosen C.A. Structural and functional characterization of human immunodeficiency virus tat protein. J Virol. 63:1989;1-8.
10. Frankel A.D., Chen L., Cotter R.J., Pabo C.O. Dimerization of the tat protein from human immunodeficiency virus A cysteine-rich peptide mimics the normal metal-linked dimer interface . Proc Natl Acad Sci USA. 85:1988;6297-6300.
11. Endo S., Kubota S., Siomi H., Adachi A., Oroszlan S., Maki M., Hatanaka M. A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization. Virus Genes. 3:1989;99-110.
12. Hauber J., Malim M.H., Cullen B.R. Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol. 63:1989;1181-1187.
13. Calnan B.J., Biancalana S., Hudson D., Frankel A.D. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev. 5:1991;201-210.
14. Kao S.-Y., Calman A.F., Luciw P.A., Peterlin B.M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature. 330:1987;489-493.
15. Feinberg M.B., Baltimore D., Frankel A.D. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA. 88:1991;4045-4049.
16. Muesing M.A., Smith D.H., Capon D.J. Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell. 48:1987;691-701.
17. Feng S., Holland E.C. HIV-1 tat trans-activation requires the loop sequence within tar. Nature. 334:1988;165-167.
18. Hauber J., Cullen B.R. Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat. J Virol. 62:1988;673-679.
19. Berkhout B., Jeang K.-T. trans Activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin A quantitative analysis . J Virol. 63:1989;5501-5504.
20. Garcia J.A., Harrich D., Soultanakis E., Wu F., Mitsuyasu R., Gaynor R.B. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J. 8:1989;765-778.
21. Marciniak R.A., Sharp P.A. HIV-1 Tat protein promotes formation of more-processive elongation complexes. EMBO J. 10:1991;4189-4196.
22. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., Wingfield P., Gallo R.C. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 67:1993;277-287.
23. Green M., Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55:1988;1179-1188.
24. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1988;1189-1193.
25. Buonaguro L., Barillari G., Chang H.K., Bohan C.A., Kao V., Morgan R., Gallo R.C., Ensoli B. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol. 66:1992;7159-7167.
26. Scala G., Ruocco M.R., Ambrosino C., Mallardo M., Giordano V., Baldassarre F., Dragonetti E., Quinto I., Venuta S. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med. 179:1994;961-971.
27. Westendorp M.O., Li-Weber M., Frank R.W., Krammer P.H. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol. 68:1994;4177-4185.
28. Taylor J.P., Cupp C., Diaz A., Chowdhury M., Khalili K., Jimenez S.A., Amini S. Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. Proc Natl Acad Sci USA. 89:1992;9617-9621.
29. Li C.J., Wang C., Friedman D.J., Pardee A.B. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 92:1995;5461-5464.
30. Zauli G., Gibellini D., Caputo A., Bassini A., Negrini M., Monne M., Mazzoni M., Capitani S. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood. 86:1995;3823-3834.
31. Huang L., Li C.J., Pardee A.B. Human immunodeficiency virus type 1 TAT protein activates B lymphocytes. Biochem Biophys Res Commun. 237:1997;461-464.
32. Albini A., Barillari G., Benelli R., Gallo R.C., Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA. 92:1995;4838-4842.
33. Albini A., Fontanini G., Masiello L., Tacchetti C., Bigini D., Luzzi P., Noonan D.M., Stetler-Stevenson W.G. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product Inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2 . AIDS. 8:1994;1237-1244.
34. Klagsbrun M., Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell. 67:1991;229-231.
35. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 64:1991;841-848.
36. Tessler S., Rockwell P., Hicklin D., Cohen T., Levi B.Z., Witte L., Lemischka I.R., Neufeld G. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem. 269:1994;12456-12461.
37. Albini A., Benelli R., Presta M., Rusnati M., Ziche M., Rubartelli A., Paglialunga G., Bussolino F., Noonan D. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene. 12:1996;289-297.
38. Sommer A., Rifkin D.B. Interaction of heparin with human basic fibroblast growth factor Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan . J Cell Physiol. 138:1989;215-220.
39. Watson K., Gooderham N.J., Davies D.S., Edwards R.J. Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Biochem Pharmacol. 57:1999;775-783.
40. Kashanchi F., Sadaie M.R., Brady J.N. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs. Virology. 227:1997;431-438.
41. Armes J. A review of Kaposi's sarcoma. Adv Cancer Res. 53:1989;73-87.
42. Friedman-Kien A.E., Laubenstein L.J., Rubinstein P., Buimovici-Klein E., Marmor M., Stahl R., Spigland I., Kim K.S., Zolla-Pazner S. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med. 96:1982;693-700.
43. Safai B., Johnson K.G., Myskowski P.L., Koziner B., Yang S.Y., Cunningham-Rundles S., Godbold J.H., Dupont B. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 103:1985;744-750.
44. Ensoli B., Gendelman R., Markham P., Fiorelli V., Colombini S., Raffeld M., Cafaro A., Chang H.K., Brady J.N., Gallo R.C. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 371:1994;674-680.
45. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., Moore P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1994;1865-1869.
46. Vogel J., Hinrichs S.H., Reynolds R.K., Luciw P.A., Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature. 335:1988;606-611.
47. Corallini A., Altavilla G., Pozzi L., Bignozzi F., Negrini M., Rimessi P., Gualandi F., Barbanti-Brodano G. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res. 53:1993;5569-5575.
48. Barnett S.W., Murthy K.K., Herndier B.G., Levy J.A. An AIDS-like condition induced in baboons by HIV-2. Science. 266:1994;642-646.
49. Barillari G., Buonaguro L., Fiorelli V., Hoffman J., Michaels F., Gallo R.C., Ensoli B. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol. 149:1992;3727-3734.
50. Steinaa L., Sorensen A.M., Nielsen J.O., Hansen J.E. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Arch Virol. 139:1994;263-271.
51. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Roderigo G., De Rosa V., Zauli G., Lolli S., Capitani S., La Placa M. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol. 10:1995;408-416.
52. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Zauli G., La Placa M. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin Diagn Lab Immunol. 3:1996;230-232.
53. Blazevic V., Ranki A., Mattinen S., Valle S.L., Koskimies S., Jung G., Krohn K.J. Helper T-cell recognition of HIV-1 Tat synthetic peptides. J Acquir Immune Defic Syndr. 6:1993;881-890.
54. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312:1984;763-767.
55. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckman J.C., Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 312:1984;767-768.
56. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor . Science. 272:1996;872-877.
57. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., Springer T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 382:1996;829-833.
58. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., Schwartz O., Heard J.M., Clark-Lewis I., Legler D.F., Loetscher M., Baggiolini M., Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 382:1996;833-835.
59. Schols D., Pauwels R., Desmyter J., De Clercq E. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology. 175:1990;556-561.
60. Callahan L.N., Phelan M., Mallinson M., Norcross M.A. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol. 65:1991;1543-1550.
61. Lederman S., Gulick R., Chess L. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J Immunol. 143:1989;1149-1154.
62. Parish C.R., Low L., Warren H.S., Cunningham A.L. A polyanion binding site on the CD4 molecule. Proximity to the HIV-gp120 binding region. J Immunol. 145:1990;1188-1195.
63. Rusnati M., Coltrini D., Oreste P., Zoppetti G., Albini A., Noonan D., di Fagagna F., Giacca M., Presta M. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem. 272:1997;11313-11320.
64. Ito M., Baba M., Sato A., Pauwels R., De Clercq E., Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res. 7:1987;361-367.
65. Ueno R., Kuno S. Anti-HIV synergism between dextran sulphate and zidovudine. Lancet. 2:1987;796-797.
66. Baba M., Snoeck R., Pauwels R., De Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 32:1988;1742-1745.
67. Shaunak S., Gooderham N.J., Edwards R.J., Payvandi N., Javan C.M., Baggett N., MacDermot J., Weber J.N., Davies D.S. Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br J Pharmacol. 113:1994;151-158.
68. Cruikshank W.W., Doctrow S.R., Falvo M.S., Huffman K., Maciaszek J., Viglianti G., Raina J., Kornfeld H., Malfroy B. A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication. J Acquir Immune Defic Syndr Hum Retrovirol. 14:1997;193-203.
69. Mhashilkar A.M., Bagley J., Chen S.Y., Szilvay A.M., Helland D.G., Marasco W.A. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14:1995;1542-1551.
70. Pilkington G.R., Duan L., Zhu M., Keil W., Pomerantz R.J. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins Direct selection from a combinatorial phage display library . Mol Immunol. 33:1996;439-450.
71. Lisziewicz J., Sun D., Lisziewicz A., Gallo R.C. Antitat gene therapy A candidate for late-stage AIDS patients . Gene Ther. 2:1995;218-222.
72. Zhou C., Bahner I.C., Larson G.P., Zaia J.A., Rossi J.J., Kohn E.B. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene. 149:1994;33-39.
73. Loret E.P., Vives E., Ho P.S., Rochat H., Van Rietschoten J., Johnson W.C. Jr. Activating region of HIV-1 Tat protein, Vacuum UV circular dichroism and energy minimization. Biochemistry. 30:1991;6013-6023.
74. Bayer P., Kraft M., Ejchart A., Westendorp M., Frank R., Rosch P. Structural studies of HIV-1 Tat protein. J Mol Biol. 247:1995;529-535.
75. Vives E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 272:1997;16010-16017.
76. Mann D.A., Frankel A.D. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10:1991;1733-1739.
77. Albini A., Soldi R., Giunciuglio D., Giraudo E., Benelli R., Primo L., Noonan D., Salio M., Camussi G., Rockl W., Bussolino F. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med. 2:1996;1371-1375.
78. 5 integrin to the basic domain of the HIV Tat protein and vitronectin. J Cell Biol. 121:1993;461-468.
79. Weeks B.S., Desai K., Loewenstein P.M., Klotman M.E., Klotman P.E., Green M., Kleinman H.K. Identification of a novel cell attachment domain in the HIV-1 Tat protein and its 90-kDa cell surface binding protein. J Biol Chem. 268:1993;5279-5284.
80. Chen L.L., Frankel A.D., Harder J.L., Fawell S., Barsoum J., Pepinsky B. Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin. Anal Biochem. 227:1995;168-175.
81. Rice A.P., Carlotti F. Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein. J Virol. 64:1990;1864-1868.
82. Anderson D.C., Nichols E., Manger R., Woodle D., Barry M., Fritzberg A.R. Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide. Biochem Biophys Res Commun. 194:1993;876-884.
83. Kim D.T., Mitchell D.J., Brockstedt D.G., Fong L., Nolan G.P., Fathman C.G., Engleman E.G., Rothbard J.B. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol. 159:1997;1666-1668.
84. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA. 91:1994;664-668.
85. Vocero Akbani A.M., Vander Heyden N., Lissy N.A., Ratner L., Dowdy S.F. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med. 5:1999;29-33.
86. Salvesen G.S., Dixit V.M. Caspases Intracellular signaling by proteolysis . Cell. 91:1997;443-446.
87. Henkart P.A. ICE family proteases Mediators of all apoptotic cell death? Immunity. 4:1996;195-201.
88. Cohen G.M. Caspases The executioners of apoptosis . Biochem J. 326:1997;1-16.
89. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:1998;43-50.